Regeneron/Roche: Independent Data Monitoring Committee finds clear efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 outpatient outcomes trial Donnerstag, 25. Februar 2021 - 13:34

Investor Update

Independent Data Monitoring Committee finds clear efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 outpatient outcomes trial

Dear Investor,

Please find attached a press release from our partner Regeneron:

Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com	Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com	Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com	Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com